Loading...
Market
How will Sage Therapeutics stock move by March 31, 2025, after Biogen acquisition proposal?
3
Sage Therapeutics•Sage•Biogen•Chris Viehbacher•Stoke Therapeutics•Phase•JPMorgan Healthcare Conference
Resolution / Starting Odds
Increases by more than 50% • 25%
Increases by 30-50% • 25%
Remains stable (±10%) • 25%
Decreases by more than 10% • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Biogen Proposes $442 Million Acquisition of Sage Therapeutics at $7.22 Per Share, Offering 30% Premium as Stock Jumps 35%
Jan 13, 2025, 10:30 AM
Biogen Inc. ($BIIB) has made a nonbinding acquisition proposal to Sage Therapeutics ($SAGE), offering $7.22 per share, which represents a 30% premium over Sage's recent trading price. The total value of the proposed acquisition amounts to approximately $442 million. Following the announcement, Sage Therapeutics' stock surged by 35%, reflecting investor optimism regarding the potential deal. Biogen's CEO, Chris Viehbacher, indicated that the company is actively seeking opportunities in the biotech sector, stating, 'We will be doing deals.' While he did not confirm specific targets, he was asked about the possibility of acquiring Stoke Therapeutics, which is preparing for Phase 3 trials for its treatment of Dravet syndrome. The ongoing discussions and market reactions are expected to be highlighted during the upcoming JPMorgan Healthcare Conference.
View original story
Similar markets
Acquisition completed • 25%
Other outcome • 25%
Offer revised • 25%
Offer rejected • 25%
Other actions • 25%
Increase offer • 25%
Withdraw offer • 25%
Proceed with acquisition • 25%
No acquisitions completed • 25%
Successful acquisition of another biotech • 25%
Successful acquisition of Sage Therapeutics • 25%
Multiple acquisitions completed • 25%
Decrease to between $400M and $500M • 25%
Decrease below $400M • 25%
Increase to over $600M • 25%
Remain between $500M and $600M • 25%
Underperforms the biotech index • 25%
Outperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Highly volatile with no clear trend • 25%
